11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Denosumab

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Denosumab

Denosumab

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Läkemedelsverket. Läkemedel vid osteoporos för att förhindra benskörhetsfrakturer - behandlingsrekommendation. Läkemedelsverket [www]. [updated 2020-04-30, cited 2020-06-11].

  2. Kaufman JM, Lapauw B, Goemaere S. Current and future treatments of osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2014;28(6):871-84.

  3. Adler RA. Update on osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2018;32(5):759-772.

  4. PROLIA (denosumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2020-02-11, cited 2020-06-24].

  5. Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. Bone. 2014;59:105-13.

  6. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-65.

  7. Orwoll E, Teglbjærg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97:3161-9.

  8. Doshi S, Sutjandra L, Zheng J, Sohn W, Peterson M, Jang G et al. Denosumab dose selection for patients with bone metastases from solid tumors. Clin Cancer Res. 2012;18:2648-57.

  9. Adler RA, Gill RS. Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interv Aging. 2011;6:119-24.

  10. Huynh AL , Baker ST, Stewardson AJ, Johnson DF. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf. 2016;25(11):1274-1278.

  11. Tsvetov G, Amitai O, Shochat T, Shimon I, Akirov A, Diker-Cohen T. Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low? . Osteoporos Int. 2020;31(4):655-665.

  12. Prolia (denosumab). DailyMed [www]. US National Library of Medicine. [updated 2020-03-22, cited 2020-06-24].

  13. Martín-Merino E, Huerta-Álvarez C, Prieto-Alhambra D, Montero-Corominas D. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis. Arch Osteoporos. 2017;12(1):39.

  14. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Läkemedelsverket. Läkemedel vid osteoporos för att förhindra benskörhetsfrakturer - behandlingsrekommendation. Läkemedelsverket [www]. [updated 2020-04-30, cited 2020-06-11].
  2. Kaufman JM, Lapauw B, Goemaere S. Current and future treatments of osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2014;28(6):871-84.
  3. Adler RA. Update on osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2018;32(5):759-772.
  4. PROLIA (denosumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2020-02-11, cited 2020-06-24].
  5. Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. Bone. 2014;59:105-13.
  6. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-65.
  7. Orwoll E, Teglbjærg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97:3161-9.
  8. Doshi S, Sutjandra L, Zheng J, Sohn W, Peterson M, Jang G et al. Denosumab dose selection for patients with bone metastases from solid tumors. Clin Cancer Res. 2012;18:2648-57.
  9. Adler RA, Gill RS. Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interv Aging. 2011;6:119-24.
  10. Huynh AL , Baker ST, Stewardson AJ, Johnson DF. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf. 2016;25(11):1274-1278.
  11. Tsvetov G, Amitai O, Shochat T, Shimon I, Akirov A, Diker-Cohen T. Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low? . Osteoporos Int. 2020;31(4):655-665.
  12. Prolia (denosumab). DailyMed [www]. US National Library of Medicine. [updated 2020-03-22, cited 2020-06-24].
  13. Martín-Merino E, Huerta-Álvarez C, Prieto-Alhambra D, Montero-Corominas D. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis. Arch Osteoporos. 2017;12(1):39.
  14. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]